Our study here suggests that Shh signaling-mediated Bcl2 upregulation can be one of the major players leading to poor outcomes in non-compliant patients and CML-variants. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.